WGS

GeneDx Holdings Corp.

$54.83

-16.57%
SectorHealthcareIndustryDiagnostics & ResearchCountryUnited States

GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.

Source: Yahoo Finance
AI summary

Price & performance

1M-18.6%
3M-29.6%
YTD-58.6%
1Y-61.6%
52-week range—
Beta1.50
Full chart and returns against a benchmark

Q-Score

58/ 100

Quality against peers; 50 is the peer median.

Growth68
Risk42
Performance79
Valuation47
Profitability50
Leverage41
Sentiment83
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$427.5M+40.0%
Net income-$21M
Net margin-4.9%+12.2 pts
Historical fundamentals

Red flags in filings

1active red flag
Material weakness in controlsFeb 23, 2026
Filings, findings and the timeline

Revenue exposure

Largest customer39%
Regions, segments, customers and suppliers

Valuation

WGSIndustryP/E—41.31P/S3.555.66EV/EBITDA—31.63P/B6.684.91PEG—3.59
Dividend yield0.00%
Every valuation metric

Earnings

Nov 9next report, after the close
EPS estimate$0.07
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate